Opium (Opioid) Addiction - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Opium (Opioid) Addiction - Pipeline Review, H2 2018’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction

- The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects

- The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adapt Pharma Ltd

Addex Therapeutics Ltd

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab’entech SA

Indivior Plc

Insys Therapeutics Inc ...

Adapt Pharma Ltd

Addex Therapeutics Ltd

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab’entech SA

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Serina Therapeutics Inc

Syntropharma Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Opium (Opioid) Addiction – Overview 6

Opium (Opioid) Addiction – Therapeutics Development 7

Opium (Opioid) Addiction ...

Table of Contents

Table of Contents 2

Introduction 5

Opium (Opioid) Addiction – Overview 6

Opium (Opioid) Addiction – Therapeutics Development 7

Opium (Opioid) Addiction – Therapeutics Assessment 16

Opium (Opioid) Addiction – Companies Involved in Therapeutics Development 24

Opium (Opioid) Addiction – Drug Profiles 34

Opium (Opioid) Addiction – Dormant Projects 106

Opium (Opioid) Addiction – Discontinued Products 107

Opium (Opioid) Addiction – Product Development Milestones 108

Appendix 115

List of Tables

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Opium (Opioid) Addiction – Pipeline by Adapt Pharma Ltd, H2 2018

Opium (Opioid) Addiction – Pipeline by Addex Therapeutics Ltd, H2 2018

Opium (Opioid) Addiction – Pipeline by Aoxing Pharmaceutical Company Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by BioCorRx Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by BioDelivery Sciences International Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by Camurus AB, H2 2018

Opium (Opioid) Addiction – Pipeline by Fab’entech SA, H2 2018

Opium (Opioid) Addiction – Pipeline by Indivior Plc, H2 2018

Opium (Opioid) Addiction – Pipeline by Insys Therapeutics Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by iX Biopharma Ltd, H2 2018

Opium (Opioid) Addiction – Pipeline by Novartis AG, H2 2018

Opium (Opioid) Addiction – Pipeline by Omeros Corp, H2 2018

Opium (Opioid) Addiction – Pipeline by Opiant Pharmaceuticals Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by Orexo AB, H2 2018

Opium (Opioid) Addiction – Pipeline by Pfizer Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by Relmada Therapeutics Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by Serina Therapeutics Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by Syntropharma Ltd, H2 2018

Opium (Opioid) Addiction – Pipeline by Titan Pharmaceuticals Inc, H2 2018

Opium (Opioid) Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H2 2018

Opium (Opioid) Addiction – Dormant Projects, H2 2018

Opium (Opioid) Addiction – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports